Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts
- PMID: 8641323
- DOI: 10.1007/BF00194951
Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts
Abstract
In a closed metabolic ward the pharmacokinetics of methadone and its primary metabolite (EDDP) were studied in 20 long-term opiate addicts. After administration of the daily oral dose of methadone HCl (mean 60 mg, range 10-225 mg) blood samples were taken and analysed, using a newly developed high-performance liquid chromatography (HPLC) method. The steady-state plasma concentrations of the 20 subjects varied from 65-630 ng x ml(-1) and from 5 to 55 ng x ml(-1), whereas the peak concentrations were 124-1255 ng x ml(-1) and 10-301 ng x ml(-1) for methadone and the AUC(0-24 h) for EDDP varied from 5.9 to 44.6, indicating interindividual differences in metabolic activity. In 19 out of 20 subjects the pharmacokinetics of methadone are best described using a two-compartment model. The mean body clearance was 1.64 ml x min(-1) x kg(-1), whereas the mean elimination rate constant (beta) and plasma half-life (t1/2beta) were 0.026 x h(-1) (range 0.013-0.053 x h(-1)) and 31.2 h (range 13-53 h), respectively. Differences of gender were also found. A poor correlation was found between the methadone dose and the steady-state level. A much better correlation was found between the normalized steady-state level and the body clearance.
Similar articles
-
Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.Br J Clin Pharmacol. 2000 Nov;50(5):427-40. doi: 10.1046/j.1365-2125.2000.00272.x. Br J Clin Pharmacol. 2000. PMID: 11069437 Free PMC article.
-
An enantiomer-selective liquid chromatography-tandem mass spectrometry method for methadone and EDDP validated for use in human plasma, urine, and liver microsomes.J Anal Toxicol. 2008 Apr;32(3):208-19. doi: 10.1093/jat/32.3.208. J Anal Toxicol. 2008. PMID: 18397572 Clinical Trial.
-
Quantitation of methadone and metabolite in patients under maintenance treatment.J Anal Toxicol. 2014 Nov-Dec;38(9):660-6. doi: 10.1093/jat/bku096. Epub 2014 Aug 8. J Anal Toxicol. 2014. PMID: 25106416
-
High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.Clin Pharmacokinet. 1986 Mar-Apr;11(2):87-106. doi: 10.2165/00003088-198611020-00001. Clin Pharmacokinet. 1986. PMID: 3514045 Review.
-
Methadone--metabolism, pharmacokinetics and interactions.Pharmacol Res. 2004 Dec;50(6):551-9. doi: 10.1016/j.phrs.2004.05.002. Pharmacol Res. 2004. PMID: 15501692 Review.
Cited by
-
Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.Anesthesiology. 2015 Nov;123(5):1142-53. doi: 10.1097/ALN.0000000000000867. Anesthesiology. 2015. PMID: 26389554 Free PMC article. Clinical Trial.
-
Dose-concentration relationships of methadone and EDDP in hair of patients on a methadone-maintenance program.Forensic Sci Med Pathol. 2005 Jun;1(2):97-103. doi: 10.1385/FSMP:1:2:097. Forensic Sci Med Pathol. 2005. PMID: 25869947
-
The influence of sex on pharmacokinetics.Clin Pharmacokinet. 2003;42(2):107-21. doi: 10.2165/00003088-200342020-00001. Clin Pharmacokinet. 2003. PMID: 12537512 Review.
-
Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.Br J Clin Pharmacol. 2009 Jan;67(1):29-37. doi: 10.1111/j.1365-2125.2008.03312.x. Br J Clin Pharmacol. 2009. PMID: 19133059 Free PMC article.
-
Integrating in vitro data and physiologically based kinetic modeling-facilitated reverse dosimetry to predict human cardiotoxicity of methadone.Arch Toxicol. 2020 Aug;94(8):2809-2827. doi: 10.1007/s00204-020-02766-7. Epub 2020 May 4. Arch Toxicol. 2020. PMID: 32367273 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous